KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $47.0 million.

  • Halozyme Therapeutics' Change in Accured Expenses rose 69.10% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year increase of 277.94%. This contributed to the annual value of $47.0 million for FY2024, which is 474.57% up from last year.
  • As of FY2024, Halozyme Therapeutics' Change in Accured Expenses stood at $47.0 million, which was up 474.57% from -$12.5 million recorded in FY2023.
  • Halozyme Therapeutics' Change in Accured Expenses' 5-year high stood at $47.0 million during FY2024, with a 5-year trough of -$41.2 million in FY2020.
  • Its 3-year average for Change in Accured Expenses is $19.7 million, with a median of $24.5 million in 2022.
  • In the last 5 years, Halozyme Therapeutics' Change in Accured Expenses plummeted by 988.49% in 2020 and then spiked by 2,002.40% in 2022.
  • Halozyme Therapeutics' Change in Accured Expenses (Yearly) stood at -$41.2 million in 2020, then spiked by 102.83% to $1.2 million in 2021, then skyrocketed by 2,002.40% to $24.5 million in 2022, then crashed by 151.14% to -$12.5 million in 2023, then spiked by 474.57% to $47.0 million in 2024.